1. Introduction {#sec1-pharmaceuticals-13-00191}
===============

The interest in alternative plants with a health-promoting potential has been growing in recent years not only in the pharmaceutical and cosmetic industries but also in the food industry where they are expected to contribute to the design of novel functional food. Therefore, it is believed that various morphological parts of *Sanguisorba officinalis* L. represent a good source of compounds exhibiting the aforementioned properties \[[@B1-pharmaceuticals-13-00191]\].

*S. officinalis* L. (great burnet or burnet bloodwort) is a species belonging to the Rosaceae family. It grows wild in Asia and Europe (except for the northern regions \[[@B1-pharmaceuticals-13-00191],[@B2-pharmaceuticals-13-00191]\]. This melliferous, perennial plant usually occurs on arid and semi-arid grasslands and blooms from June till September. Its shoots can grow up to ca. 1.2--1.5 m. *S. officinalis* L. is resistant to frost as well as to diseases. It has been used for culinary purposes as an additive to salads and in animal feeding as an additive to feed mixtures due to its high nutritional value \[[@B3-pharmaceuticals-13-00191]\]. However, in folk medicine of both the Far East and Europe, *S. officinalis* L. was used as an herbal medicine in relieving inflammation, controlling external and internal bleeding, in the treatment of ulcers, burns, eczema, acne, as well as diarrhea \[[@B4-pharmaceuticals-13-00191],[@B5-pharmaceuticals-13-00191]\]. In turn, the available experimental data prove a number of its biological properties, e.g., anti-inflammatory \[[@B3-pharmaceuticals-13-00191]\], anticancer \[[@B6-pharmaceuticals-13-00191]\], antiviral \[[@B7-pharmaceuticals-13-00191]\], antioxidant \[[@B1-pharmaceuticals-13-00191]\], prevention of the Alzheimer's disease \[[@B3-pharmaceuticals-13-00191]\], and anti-wrinkle effects. \[[@B8-pharmaceuticals-13-00191]\]. In addition, the above studies have shown that all the biological properties exhibited by this perennial plant are due to a broad range of its bioactive compounds such as phenolic acids, tannins, flavonoids, triterpenes, and polysaccharides \[[@B1-pharmaceuticals-13-00191],[@B3-pharmaceuticals-13-00191],[@B4-pharmaceuticals-13-00191],[@B5-pharmaceuticals-13-00191],[@B6-pharmaceuticals-13-00191],[@B7-pharmaceuticals-13-00191],[@B8-pharmaceuticals-13-00191]\]. The richness of these compounds is sought in alternative plant sources that could be used in the treatment and prevention of many diseases and even as a dietary component \[[@B9-pharmaceuticals-13-00191]\].

Considering a number of biological properties of *S. officinalis* L., this plant has a high nutraceutical potential. However, there are a few reports on the profile and content of secondary metabolites in all of its morphological parts, which may differ and therefore exhibit various properties. Thus, research was undertaken into the accurate characterization of flowers, leaves, stalks, and roots in terms of the profile and content of polyphenols using the highly sensitive LC-DAD-ESI-QTOF-MS/MS technique. Analyses were also conducted to determine the in vitro antioxidant, antiproliferative, and antidiabetic activity for the individual morphological parts of *S. officinalis* L. This study aims to provide valuable information about differences in contents of bioactive compounds and their biological properties in the flowers, leaves, stalks, and roots of *S. officinalis* L., which will be used to compose not only functional foods but also nutraceuticals in the future.

2. Results and Discussion {#sec2-pharmaceuticals-13-00191}
=========================

2.1. Identification of Polyphenolic Compounds {#sec2dot1-pharmaceuticals-13-00191}
---------------------------------------------

The present study involved a thorough identification of the profile of bioactive compounds in extracts from leaves, flowers, stalks, and roots of *Sanguisorba officinalis* L. plant with the use of an ultrasensitive LC-DAD-ESI-QTOF-MS/MS method in the negative and positive ion mode. In total, 130 compounds were identified in extracts from the selected morphological parts of *S. officinalis* L., including 77 hydrolyzable tannins, 9 sanguiins, 3 sanguisorbic acids, 13 phenolic acids, 6 anthocyanins, 12 catechins and proanthocyanidins, and 9 flavonols, as well as 1 triterpenoid saponins ([Table 1](#pharmaceuticals-13-00191-t001){ref-type="table"}; [Figures S1--S4](#app1-pharmaceuticals-13-00191){ref-type="app"}). In turn, 62 compounds were identified in *S. officinalis* L. for the first time ever, including 42 hydrolyzable tannins, 5 sanguiins, 8 phenolic acids, 2 anthocyanins, 1 proanthocyanidins, and 3 flavonols as well as 1 triterpenoid saponins. Peaks were identified based on the determined exact molecular weights, peak retention times, primary ions from MS fragmentation, and comparison of data obtained with commercial standards and literature findings ([Table 1](#pharmaceuticals-13-00191-t001){ref-type="table"}). However, the profile of the compounds examined was strongly dependent on the morphological part of the plant, since 70, 76, 66, and 62 compounds were identified in the flowers, leaves, roots, and stalks, respectively.

The prevailing group of polyphenolic compounds were hydrolyzable tannins belonging to the family of tannins and being hydrolyzed conjugates that contain one or more hexahydroxydiphenoyl (HHDP) groups, thus leading to the esterification of sugars, glucose in particular. During fragmentation of the primary ions, losses observed were typical of these compounds and involved losses of galloyl, hexahydroxydiphenoyl, gallic acid, HHDP glucose, galloyl-glucose, and galloyl-HHDP-glucose residues with 152, 302, 170, 482, 332, 634 Da, respectively. Additionally, fragments were noted at *m*/*z* 169 and at *m*/*z* 301 formed through lactonization of the characteristic hexahydroxydiphenoyl group to ellagic acid. These compounds comprise typical galloyl and HHDP groups, respectively, which have earlier been described in the available literature \[[@B1-pharmaceuticals-13-00191],[@B2-pharmaceuticals-13-00191],[@B3-pharmaceuticals-13-00191],[@B9-pharmaceuticals-13-00191],[@B10-pharmaceuticals-13-00191],[@B11-pharmaceuticals-13-00191]\]. Furthermore, if ellagitannin or galloyl derivates are composed of one or a few galloyl groups taking part in sugar synthesis, the fragmentary ion first discards a molecule of gallic acid and then a galloyl group or groups during fragmentation \[[@B10-pharmaceuticals-13-00191]\]. Among the 77 compounds, only 36 had previously been identified in *S. officinalis* L., and they all were methyl-6-*O*-galloyl-β-[d]{.smallcaps}-glucopyranoside (peak 17, 64; *m*/*z* 345), pedunculagin1 (18, 23, 29; *m*/*z* 785), galloyl-HHDP-glucose otherwise called corilagin isomer (25, 44, 55; *m*/*z* 633), di-galloyl-glucoside (37; *m*/*z* 483), methyl-4,6-digalloyl-*β*-[d]{.smallcaps}-glucopyranoside (50, 62, 71, 88; *m*/*z* 497), HHDP-galloyl-glucose (53; *m*/*z* 633), ellagic acid pentoside (60, 99; *m*/*z* 433), ellagic acid hexoside (67, 68, 102; *m*/*z* 463), di-galloyl hexoside (72, 118; *m*/*z* 483), galloyl-bis-HHDP-glucose otherwise called potentilin/casuarictin isomer (84, 85, 95, 97, 104, 106; *m*/*z* 935), lambertianin C (86; *m*/*z* 1401), ellagic acid (108; *m*/*z* 300.99), trigalloyl-HHDP-glucose (92, 114; *m/z* 937), trigalloyl-β-D-methyl glucoside (115; *m*/*z* 649), 3,3′,4′-*O*-trimethyl ellagic acid (127, 128; *m*/*z* 343), and 3,4′-*O*-dimethyl ellagic acid (129, 130; *m*/*z* 329) \[[@B2-pharmaceuticals-13-00191],[@B3-pharmaceuticals-13-00191],[@B12-pharmaceuticals-13-00191]\]. In turn, 16 compounds had earlier been detected and identified in flowers and fruits of *Punica granatum* but in this study were for the first time detected in the morphological parts of *S. officinalis* L. These compounds were referred to as: 2,3-HHDP-(α/β)-glucose (1; *m*/*z* 481), HHDP-hexoside(2,3-(*S*)-Hexahydroxydiphenoyl-[d]{.smallcaps}-glucose) (2, 4; *m*/*z* 481), HHDP-hexoside(1-galloyl-2,3-hexahydroxydiphenoyl-α-glucose) (3; *m*/*z* 481), galloyl-hexoside(β-glucogallin) (5; *m*/*z* 331), galloyl-hexoside (7--10, 13; *m*/*z* 331), di-HHDP-glucoside (34; *m*/*z* 783), di-galloyl-HHDP-glucose (14, 56, 66; *m*/*z* 785), galloyl-HHDP-hexoside (77; *m*/*z* 633), and pentagalloyl-glucoside (111; *m*/*z* 939) \[[@B10-pharmaceuticals-13-00191],[@B13-pharmaceuticals-13-00191]\]. Another 6 compounds belonging to the group of hydrolyzable tannins were detected during identification of *Duchesnea indica* and they were: di-HHDP-glucose also known as pedunculalagin isomer (15, 20, 24, 26, 27, 30; *m*/*z* 783) \[[@B14-pharmaceuticals-13-00191]\]. However, 12 subsequent compounds were identified and determined based on their main ion and MS/MS fragmentation as β-1-*O*-galloyl-2,3-(*S*)-HHDP-[d]{.smallcaps}-glucose (28; *m*/*z* 633), methyl ellagic acid-pentoside (35; *m*/*z* 477), HHDP-NHTP-glucose (47, 51; *m*/*z* 933), castalagin/vescalagin isomer (58, 70, 79, 81, 98, 110; *m*/*z* 933), HHDP-NHTP-glucose-galloyl-di-HHDP-glucose (cocciferind2) (82; *m*/*z* 933), and tetragalloyl-glucose (100; *m*/*z* 787). They had earlier been detected in various plant materials like *Castanea sativa* Miller, *Quercus suber* L., *Betula pubescens*, raspberry fruits, and oak \[[@B15-pharmaceuticals-13-00191],[@B16-pharmaceuticals-13-00191],[@B17-pharmaceuticals-13-00191],[@B18-pharmaceuticals-13-00191]\]. However, 8 compounds were identified for the first time ever. Compound No. 6 was tentatively identified as galloyl-pentoside based on the primary ion at *m*/*z* 301 and the loss of the pentose group (132 Da) giving a peak at *m*/*z* 169. Compound No. 49 was tentatively identified as HHDP-glucose based the primary ion at *m/z* 481 and MS/MS fragment at *m/z* 301. In the case of compound No. 54, the primary peak was at *m*/*z* at 345 due to the loss of a 176 Da residue that resulted in a peak formed at *m*/*z* 169, which was tentatively identified as galloyl-glucoronide. Compounds No. 73 and 74 were tentatively identified as eucaglobulin based on the primary ion at *m*/*z* 497 and MS/MS fragmentary ions revealing peaks at *m*/*z* 345, 327, 313, 183, and 169. In turn, compounds No. 93 and 94 were tentatively described as ellagic acid-hexoside-pentoside based the primary ion at *m*/*z* 595 and its fragmentation ions at *m*/*z* 433 and 301 due to the loss of a hexose residue (162 Da) and a pentose residue (132 Da). Finally, compound No. 113 was tentatively identified as methyl galloyl-glucoside based on the primary peak at *m*/*z* 345 and the loss of a glucosyl residue (162 Da), yielding a base peak at *m*/*z* 183.

Another described class of polyphenolic compounds belonging to hydrolyzed tannins were sanguiins. Among the 9 identified compounds, only 4 had earlier been detected in *S. officinalis* L. as sanguiin H-6 (11, 89; *m*/*z* 1870), sanguiin H-4 (41; *m*/*z* 633), and sanguiin H-10 isomer (48; *m*/*z* 783) by Karkanis et al. \[[@B3-pharmaceuticals-13-00191]\] and Zhu et al. \[[@B2-pharmaceuticals-13-00191]\], whereas the other 5 were never identified, as shown by literature data. Therefore, based on the primary peak at *m*/*z* 785 and MS/MS fragmentation peaks at *m*/*z* 633 and 301, and due to the loss of 152 and 332 Da groups, compounds No. 65, 69, and 96 were tentatively identified as sanguiin H-1. In turn, compounds No. 119 and 122 were tentatively identified as sanguiin H-7 and sanguiin H-7 isomers considering their primary ion at *m*/*z* 801 and fragmentation peaks at *m*/*z* 649 and 301 resulting from the loss of 152, 332, and 16 Da.

In contrast, sanguisorbic acids, belonging to the hydrolyzed tannins, also have been previously defined for these plants by Zhu et al. \[[@B2-pharmaceuticals-13-00191]\] as sanguisorbic acid dilactone (9, 12; *m*/*z* 469) and sanguisorbic acid glucoside (52; *m*/*z* 667). These compounds were determined only in the leaves, stalks, and roots of *S. officinalis* L. Moreover, 1 sanguisorbigenin, belonging to the triterpenoid saponins, was detected during identification *P. granatum* \[[@B12-pharmaceuticals-13-00191]\].

UV detection at the characteristic absorption maximum between 310 and 330 nm \[[@B19-pharmaceuticals-13-00191]\] showed the presence of 13 hydroxycinnamic acids in flowers, leaves, and stalks in the case of which the esterification of their quinic acid residue occurs at positions 3, 4, and 5, but not at position 1 \[[@B19-pharmaceuticals-13-00191]\]. Of these, 5 were identified early in *S. officinalis* as caffeoylquinic acid (16, *m*/*z* 353), 3-*O*-caffeoylquinic acid (19; *m*/*z* 353), 3-*O*-*p*-coumaroylquinic acid (32; *m*/*z* 337), 5-*O*-caffeoylquinic acid (42; *m*/*z* 353), and 3-*O*-feruloylquinic acid (78; *m*/*z* 367) \[[@B12-pharmaceuticals-13-00191]\]. However, 4 more were previously identified in other botanical sources like *Eryngium alpinum* L. and *Chrysanthemum* as rosmarinic acid (33; *m*/*z* 359), disuccinoyl-caffeoylquinic acids (116; *m*/*z* 553), and 3,5-dicaffeoylquinic (120, 121; *m*/*z* 515), however, for the first time in *S. officinalis* L., compounds No. 123--125 were tentatively identified as caffeoyl dihexoside based on the highest peak at *m*/*z* 505 and its fragmentation yielding peaks at *m*/*z* 341 and 179 due to the loss of 2 hexose residues (162 + 162 Da). What is more, these compounds were also described for the first time ever in morphological parts of *S. officinalis* L.

Anthocyanins are natural plant pigments occurring in the plant kingdom. They were identified in the positive ion mode because they bear a positive charge and easily donate protons to free radicals under ESI conditions. In turn, their detection was carried out at the typical absorption maximum between 440 and 540 nm \[[@B10-pharmaceuticals-13-00191],[@B20-pharmaceuticals-13-00191]\]. Among the tentatively identified 6 anthocyanins, that were detected only in the flowers, only 4 were earlier determined in *S. officinalis* L. as cyanidin 3,5-diglucoside (21; *m*/*z* 611), cyanidin 3-*O*-glucoside (46; *m*/*z* 449), and cyanidin 3-malonylglucoside (76, 90; *m*/*z* 535) \[[@B12-pharmaceuticals-13-00191]\]. The other 2 compounds were described based on previous information about fragmentation of pomegranate and grape berry skin \[[@B13-pharmaceuticals-13-00191],[@B21-pharmaceuticals-13-00191]\] as cyanidin 3-*O*-rutinoside (87; *m*/*z* 595) and cyanidin 3-(6-*O*-acetyl)-glucoside (91; *m*/*z* 491).

Flavan-3-ols occur as monomers, oligomers, and polymers formed by linking to (epi)catechin monomers via interflavonoid bonds (C--C) \[[@B22-pharmaceuticals-13-00191]\]. Their fragmentation proceeds through the loss of a (epi)catechin unit with a molecular weight of 289 Da. The identified proanthocyanins occurred as catechin dimers, trimers, and tetramers and were identified as A and B procyanidins \[[@B22-pharmaceuticals-13-00191]\]. These 11 compounds were characterized based on available standards and the latest research works addressing *S. officinalis* L as (+)-catechin and (−)-epicatechin (31, 40; *m*/*z* 289), B-type (epi)catechin dimmer (36, 38, 39, 63, 83; *m*/*z* 577), B-type (epi)catechin trimmer (43; *m*/*z* 865), and B-type (epi)catechin tetramer (57, 59, 80; *m*/*z* 1153) \[[@B2-pharmaceuticals-13-00191],[@B3-pharmaceuticals-13-00191]\]. In turn, compound No. 74 was tentatively identified as a A-type (epi)catechin tetramer at *m*/*z* 1153 and the base ion at *m*/*z* 289. Although it was earlier detected in black soybean \[[@B23-pharmaceuticals-13-00191]\], it was described in *S. officinalis* L. for the first time ever.

Flavonols were identified as derivatives of taxifolin, kaempferol, and quercetin based on the base fragments at *m*/*z* 300, 285, and 301. UV detection of flavonols revealed characteristic absorption maximum between 315 and 359 nm, and some of the identified compounds had additional peaks between 207 and 280 nm \[[@B24-pharmaceuticals-13-00191]\]. Besides, derivatives of these compounds are usually detected at positions C-7 and/or C-3. Fragmentation of the primary ions resulted in losses of hexose (162 Da), pentose (146 Da), and deoxyhexose (308 Da) \[[@B24-pharmaceuticals-13-00191]\]. Of the 9 flavonols initially suggested for *S. officinalis* L., only 6 have previously been described for this species as quercetin-3-*O*-glucoside (45; 463), quercetin-3-*O*-(6″-galloylglucose) (101; *m*/*z* 615), taxifolin-7-*O*-*β*-[d]{.smallcaps}-glucopyranoside (103; *m*/*z* 465), quercetin-3-*O*-glucuronide (109; *m*/*z* 477), quercetin-3-*O*-acetyl glucoside (112; *m*/*z* 505), and kaempferol-3-*O*-glucuronide (117; *m*/*z* 461) \[[@B2-pharmaceuticals-13-00191],[@B3-pharmaceuticals-13-00191],[@B12-pharmaceuticals-13-00191]\]. In turn, 3 compounds have not been previously described according to the available literature. Compound No. 61 was tentatively identified as kaempferol-di-*O*-rhamnoside based on the primary peak at *m*/*z* 577 and fragmentation peaks at *m*/*z* 431 and 285 due to the loss of two rhamnoside residues (146 + 146 Da). Another compound (103) was tentatively described as quercetin-glucoside-dirhamnoside based on the primary peak at *m*/*z* 755 and fragmentation peaks at *m*/*z* 609, 463, and 301 due to the loss of two rhamnose residues and one glycosyl residue. Finally, compound No. 107 was tentatively presented as quercetin rhamnosyl-rutinoside based on the primary peak at *m*/*z* 755 and fragmentation peaks at *m*/*z* 609 and 301.

2.2. Quantification of Polyphenolic Compounds {#sec2dot2-pharmaceuticals-13-00191}
---------------------------------------------

The content of polyphenols in the analyzed morphological parts of *S. officinalis* L. is shown in [Table 2](#pharmaceuticals-13-00191-t002){ref-type="table"}. The highest content of bioactive compounds was determined in the flowers, it reached 14,444.97 mg/100 g d.b. and was 1.5, 1.7, and 3.2 times higher than in the leaves, roots, and stalks, respectively. In turn, the content of polyphenols in the leaves + stalks of *Sanguisorba minor* Scop. was comparable to the content of these compounds in *S. officinalis* L., while the roots of *S. minor* Scop. were 4 times more abundant in the studied compounds than the roots of *S. officinalis* L. \[[@B3-pharmaceuticals-13-00191]\]. In turn, the sum of polyphenols analysed in the roots of the same species from Korea was 2 times lower than in the roots of plants grown in Poland. However, the extract from *S. officinalis* L. cultivated in China contained 3150 mg GAE/100 g dry weight polyphenols, which was 4.9, 3.2, 2.8, and 1.5 times lower compared to the flowers, leaves, roots, and stalks of the same species growing in Poland. The content of polyphenols in the leaves of green and white tea was 67.21 and 40.94 mg/g d.b. and was 1.5 and 2.4 times lower than in the leaves of the studied species, respectively \[[@B25-pharmaceuticals-13-00191]\]. Total content of polyphenols analyzed in the flowers, leaves, roots, and stalks of *S. officinalis* L. was 8.2, 8.4, 7.8, and 8.4 times higher, respectively, compared to edible flowers of *Allium schoenoprasum* (Liliaceae), *Salvia pratensis* (Lamiaceae), *Sambucus nigra* (Caprifoliaceae), *Taraxacum officinale* \[[@B26-pharmaceuticals-13-00191]\]. However, according to Zeng et al. \[[@B27-pharmaceuticals-13-00191]\] the contents of bioactive compounds in the flowers of green and black tea of *Camellia sinensis* were 2.4 and 5.4 times lower, respectively, compared to the flowers of *S. officinalis* L. Moreover, the content of bioactive compounds in the flowers and the leaves of *Punica granatum* L. was 2.2 and 6.7 times lower, respectively, than in the same morphological parts of *S. officinalis* L. \[[@B28-pharmaceuticals-13-00191]\]. In addition, the content of compounds tested in the leaves and the stalks of *Fallopia japonica* was 1.7 and 2.3 times lower, respectively, while their content in the roots of *F. japonica* was similar to *S. officinalis* L. \[[@B9-pharmaceuticals-13-00191]\]. The differences in the contents of polyphenolic compounds among individual species can be affected by various factors, such as the place of cultivation, climate, environmental conditions, and also the method of extraction and analysis \[[@B29-pharmaceuticals-13-00191]\]. Thus, the tested material is characterized by a high content of compounds exhibiting a number of biological properties and can be used to compose not only nutraceuticals in the pharmaceutical industry but also to produce functional food.

The profile and content of phenols present in various morphological parts of *S. officinalis* L. were quite diverse and strongly dependent on the morphological part tested. The flowers were dominated by hydrolyzed tannins (66.4% in all phenols) \> flavan-3-ols (13.1%) \> phenolic acids (9.9%) \> flavonols (5%) \> anthocyanins (3.8%) \> triterpenoids (1.8%). In turn, in the leaves were dominated by hydrolyzed tannins (49.3%) \> phenolic acids (20.5%) \> flavonols (19.8%) \> flavan-3-ols (7.4%) \> triterpenoids (3%). However, in the roots, hydrolyzed tannins were also the dominant class (62.1%) \> flavan-3-ols (37.3%) \> phenolic acids and flavonols (\<0.5%), whereas the stalks were dominated by hydrolyzed tannins (43.3%) \> flavan-3-ols (26.2%) \> flavonols (17.1%) \> phenolic acids (7.8%) \> triterpenes (5.5%). The analysis of phenols profile revealed flavonols to be the major group in leaf + stalks, whereas hydrolyzed tannins to be the major group in the roots of *S. minor* \[[@B3-pharmaceuticals-13-00191]\], similarly to the roots of *S. officinalis* L. and to the results presented in the work of Kim et al. \[[@B1-pharmaceuticals-13-00191]\].

Tannins are compounds that occur naturally in plants and also play a defensive role in them. They exhibit anti-inflammatory properties against inflammation of the mucous membranes and skin, as well as antiastringent, antioxidative, free radical-scavenging, and antiproliferative properties. In addition, they are also an important component of food because they affect its storage stability, taste, and color \[[@B30-pharmaceuticals-13-00191]\]. The highest content of these compounds was recorded in the flowers (9594.27 mg/100 g d.b.) and the lowest one in the stalks (1996.51 mg/100 g d.b.). According to Karkanis et al. \[[@B3-pharmaceuticals-13-00191]\], their content in *S. minor* was comparable in the leaves and stalks while 4 times higher in the roots compared to the morphological parts of *S. officinalis* L., respectively. In turn, the major compound in all morphological parts tested was Lambertian C, with its content ranging from 62% in the roots to 17% in the stalks, and similar observations were made in *S. minor* \[[@B3-pharmaceuticals-13-00191]\].

Phenolic acids are another naturally occurring class of polyphenolic compounds that have a number of biological properties, including antioxidative ones, or are used in the prevention of cardiovascular diseases. They also affect the sour and bitter taste of food of plant origin, imparting them astringent flavones \[[@B31-pharmaceuticals-13-00191]\]. They dominated in the leaves of *S. officinalis* L. and their content amounted to 2044.37 mg/100 g d.b., while their poorest presence was in the roots (only 6.64 mg/100 g d.b.). Their content in the leaves was 5.3 times higher compared to their total content in leaves and stalks of *S. minor*, but similar while comparing to the stalks of *S. officinalis* L. and *S. minor* \[[@B3-pharmaceuticals-13-00191]\]. In turn, chlorogenic acid turned out to be the major compound in the flowers, neochlorogenic acid prevailed in the stalks and leaves, while ellagic acid was found in the leaves and stalks of *S. minor* \[[@B3-pharmaceuticals-13-00191]\].

Anthocyanins occurred only in flowers, giving them an intense red color. They belong to the group of polyphenols which show a number of health-promoting properties \[[@B9-pharmaceuticals-13-00191],[@B32-pharmaceuticals-13-00191]\]. Their content was 549.57 mg/100 g d.b., and the dominant compounds were cyanidin 3-*O*-glucoside and cyanidin 3-*O*-malonylglucoside and they constituted of 62% and 28% of all anthocyanins, respectively.

Catechins and proanthocyanidins are compounds that also play an important role in the prevention of many diseases \[[@B9-pharmaceuticals-13-00191],[@B32-pharmaceuticals-13-00191]\]. Their content ranged from 739.47 to 3239.19 mg/100 g d.b. in the leaves and roots of *S. officinalis* L, respectively, and was 5.6 and 20 times higher compared to the leaves and roots of *Fallopia japonica*, respectively \[[@B9-pharmaceuticals-13-00191]\]. The dominant compounds were: B-type (epi)catechin dimmer constituting 41% in the leaves to 18% in the stalks of all flavan-3-ols, and (−)-epicatechin constituting from 37% in the stalks to 19% in the leaves. Although in *F. japonica*, the major compound was procyanidin dimer B \[[@B9-pharmaceuticals-13-00191]\].

Flavonols are also a valuable class of natural secondary metabolites due to their anti-inflammatory and antioxidative properties \[[@B9-pharmaceuticals-13-00191]\]. The highest content of these compounds was noted in the leaves and reached 1969.85 mg/100 g d.b. It was 2.7, 2.5, and 41 times higher compared to the flowers, stalks, and roots, respectively. This difference results from the fact that these compounds are mainly located in the top layer of plants, protecting them from harmful UV radiation \[[@B32-pharmaceuticals-13-00191]\]. In turn, quercetin-*O*-glucuronide was the dominant compound in the flowers, leaves, and stalks, constituting 69%, 83%, and 85% of all flavonols, respectively, whereas taxifolin 7-*O*-β-[d]{.smallcaps}-glucopyranoside prevailed in the roots, constituting 91%. These observations have also been confirmed by Kim et al. \[[@B1-pharmaceuticals-13-00191]\].

2.3. Pro-Health Properties {#sec2dot3-pharmaceuticals-13-00191}
--------------------------

The average antioxidative activity determined for *S. officinalis* L. was 4.45 mmol Troloxu (TE)/g dry basis (d.b.) in the ABTS test and 0.18 mmol TE/g d.b. in the FRAP assay ([Table 3](#pharmaceuticals-13-00191-t003){ref-type="table"}). The highest activity was determined in the leaves and was 6.63 and 0.30 mmol TE/g d.b. in the ABTS and FRAP tests, respectively. It was 1.2 and 1.6 times higher than in the stalks, 12.0 and 2.1 times higher than in the roots, and comparable to that found in the flowers for the ABTS radicals and for Fe^3+^ reduction to Fe^2+^, respectively ([Table 3](#pharmaceuticals-13-00191-t003){ref-type="table"}). Similar results of the antioxidative activity assays were obtained for the roots of *S. officinalis* gathered in China \[[@B5-pharmaceuticals-13-00191]\]. In turn, previous research shows that the antiradical activity of the leaves, stalks, and roots of *S. officinalis* L. was 6.2, 1.7, and 10.6 times higher compared to the same parts of *F. japonica* as well as 7.9, 1.8, and 9.3 times higher compared to the same parts of *F. sachalinensis*, respectively \[[@B9-pharmaceuticals-13-00191]\]. Antiradical activity for the roots was comparable to that obtained for the medical plant---*Ruta montana* \[[@B33-pharmaceuticals-13-00191]\]. Moreover, the average reducing activity of the tested parts of *S. officinalis* L. was comparable to the antioxidant potential determined for *Melissae* folium and about 6 times higher than for *Spiraea herba*, *Uvae ursi* folium, *Rubi fructose* folium, or *Fragariae herba* folium \[[@B34-pharmaceuticals-13-00191]\]. Thus, the results obtained indicate that the roots, flowers, and leaves of *S. officinalis* L. have a high ability to scavenge free radicals, which may be due to the high content of bioactive compounds determined for these morphological parts of the plant. What's more, the results presented a strong Pearson's correlation with the sum content of phenolic acids and anthocyanins and with the antioxidative activity as *r*^2^ = 0.734 and 0.539 for ABTS assay and *r*^2^ = 0.746 and 0.869 for FRAP, whereas the correlation between the reducing activity and sum of hydrolysable tannins and polyphenols was also strong *r*^2^ = 0.769 and 0.823.

The leaves, flowers, stalks, and roots of *S. officinalis* L. were also tested for their ability of inhibition of α-amylase (αA) and α-glucosidase (αG) activity, and their ability of inhibition of pancreatic lipase (LP) activity ([Table 3](#pharmaceuticals-13-00191-t003){ref-type="table"}). αA and αG are carbohydrate-degrading enzymes, but the mechanisms of their action differ; αA accelerates the hydrolysis of bonds inside a compound, whereas αG hydrolyzes α-1,4-glucosidic bonds, leading to the release of glucose absorbed by the body \[[@B35-pharmaceuticals-13-00191]\]. In turn, LP is an enzyme responsible for the degradation of triglycerides to simple lipids and fatty acids absorbable by the human body. However, it has been proved that excess fatty acids can lead to the formation of free radicals and insulin resistance \[[@B36-pharmaceuticals-13-00191]\]. Therefore, the inhibition of the above enzymes may be used in the treatment of diabetes type II or obesity \[[@B35-pharmaceuticals-13-00191]\]. The obtained results show that the highest ability to inhibit αA and αG activity was recorded for flowers of *S. officinalis* L. and reached EC~50~ 6.03 and 9.60 mg/mL, respectively. Therefore, the flowers were 1.6 and 1.3 times more active than the leaves, 4.0 and 3.3 times more active than the stalks, and 1.7 and 2.0 times more active than the roots, respectively. In turn, the highest ability to inhibit pancreatic lipase was found for the leaves of *S. officinalis* L. (EC~50~ = 18.75 mg/mL) which were 1.2, 3.0, and 3.9 times more active compared to the flowers, stalks, and roots of the tested plant, respectively. As far as the results showed that the ability to inhibit αA, αG, and LP strongly depended on the sum of flavan-3-ols and the correlations were *r*^2^ = 0.944, 0.836, and 0.593, respectively. However, in the case of phenolic acids and flavonols, the correlations were strongly negative: *r*^2^ = 0.813, 0.921, and 0.872 and *r*^2^ = 0.842, 0.825, and 0.857, respectively.

The antiproliferative potency of the flowers, leaves, roots, and stems of *S. officinalis* L. were tested against four different cancer cell lines as BxPC3 (pancreatic ductal adenocarcinoma), DLD-1 (colorectal adenocarcinoma), HCV29T (bladder cancer), and Jurkat (T-cell leukemia). This is the first report on these cancer cell lines. The effect against the used cell lines was clearly noted ([Figure 1](#pharmaceuticals-13-00191-f001){ref-type="fig"}). The extract from *S. officinalis* L. leaves significantly reduces the viability of all tested cell lines, especially DLD-1 colon cancer cells (to 19%) and Jurkat leukemia cells (to 22%). The flower extract reduced the viability of Jurkat cells to 32% and the remaining cells by 39--50%. Extract from the root showed similar results. In contrast, the extract from the stem acted the weakest on all cell lines, reducing cell viability to 85--97%. What's more, the results presented a strong Pearson's correlation between the sum of flavan-3-ols and with the viability of Jurkat leukemia cells and DLD-1 colon cancer cells---*r*^2^ = 0.731 and 0.545, while lower the viability of HCV29T cells strongly depended on anthocyanins and the correlation was *r*^2^ = 0.705. Liu et al. \[[@B37-pharmaceuticals-13-00191]\] noted that aqueous root extracts of *S. officinalis* L. showed synergic effect on inhibition of activity against HCT-116 and CPR cell lines (colon cancer) with 5-fluorouracil. Shin et al. \[[@B38-pharmaceuticals-13-00191]\] observed that the extract of *S. officinalis* L. inhibited cell growth against HSC4 and HN22 cell line (oral cancer) and induced death. According to Liu et al. \[[@B39-pharmaceuticals-13-00191]\], aqueous plant extracts of *S. officinalis* L. decreased the target Wnt and β-catenin genes by inhibiting the signal pathway of Wnt/β-catenin in cells of colorectal cancer. Moreover, Karkanis et al. \[[@B3-pharmaceuticals-13-00191]\] noted that the highest ability to inhibit of cervical carcinoma (HeLa), breast adenocarcinoma (MCF-7), and nonsmall cell lung cancer (NCl-H460) cell line was recorded for extract of roots of *S. minor*, whereas the extract of leaves + stalks of *S. minor* showed high ability to inhibit of hepatocellular carcinoma (HepG2) cell line. Thus, our own results and other authors presented that the highest cytotoxicity for the examined tumor cell lines covered depends on the analyzed morphological parts of *S. officinalis* L. and their bioactive substances. Moreover, the leaves, flowers, and roots showed high and differed antiproliferative potency to inhibit activity of various tumor cell lines.

3. Materials and Methods {#sec3-pharmaceuticals-13-00191}
========================

3.1. Material, Reagents, and Instruments {#sec3dot1-pharmaceuticals-13-00191}
----------------------------------------

Materials: *Sanguisorba officinalis* L. flowers, stalks, roots, and leaves (\~5 kg) were obtained from a private garden in Szczytna (53°33′46″ N 20°59′07″ E), Lower Silesia, Poland. The plant was collected randomly in August 2019 from different parts of field (total area of cultivation is 1 ha). Then, material was washed and dried in a freeze dryer Alpha 1-4 LSC (Christ, Osterode, Germany).

Reagents: acetonitrile, formic acid, methanol, ABTS (2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic acid), 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), 2,4,6-tri(2-pyridyl)-s-triazine (TPTZ), methanol, acetic acid, α-amylase from porcine pancreas, α-glucoamylase from *Rhizopus* sp., lipase from porcine pancreas, Antibiotic-Antimycotic Solution, and RPMI 1640 culture medium were purchased from Sigma-Aldrich (Steinheim, Germany). (−)-Epicatechin, (+)-catechin, procyanidin B2, *p*-coumaric acid, ferulic acid, 5-caffeoylquinic acid, procyanidin A2, caffeic acid, quercetin 3-*O*-rutinoside, quercetin-3-*O*-galactoside, quercetin-3-*O*-glucoside, kaempferol 3-*O*-galactoside, ellagic acid, and cyanidin-3-*O*-glucoside were purchased from Extrasynthese (Lyon, France). DMEM culture medium with 10% FBS were purchased from Gibco (Thermo Fisher Scientific, Waltham, MA, USA), and MTS solution was purchased from Promega (Madison, WI, USA).

Instruments: UV-2401 PC spectrophotometer (Shimadzu, Kyoto, Japan) for antioxidant activity; Sonic 6D, Polsonic, Warsaw, Poland, for extraction; LC-DAD-ESI-QTOF-MS/MS (ultraperformance liquid chromatography equipped with a binary solvent manager and a Q-Tof Micro Mass Spectrometer (Waters, Manchester, UK) with an ESI source operating in negative and positive modes (Waters Corporation, Milford, MA, USA) for polyphenolic compounds; and Wallac 1420 VICTOR2 Plate Reader (PerkinElmer, Waltham, MA, USA) for antiproliferative activity.

3.2. Determination of Polyphenols {#sec3dot2-pharmaceuticals-13-00191}
---------------------------------

For the extraction and determination of phenolic compounds, a protocol described before by Lachowicz et al. \[[@B9-pharmaceuticals-13-00191]\] was followed. Briefly, samples (0.1 g) were mixed with 5 mL of 30% of UPLC-grade methanol. The extracts were sonicated for 20 min and centrifuged (at 19,000× *g*/10 min). Finally, the extracts were filtered by hydrophilic PTFE 0.20 μm membrane (Millex Samplicity Filter, Darmstadt, Germany) and used for testing.

The runs were monitored at the following wavelengths: phenolic acids at 320 nm, flavonols at 360 nm, anthocyanins at 520 nm, flavan-3-ols at 280 nm, and hydrolysable tannins at 240 nm. Separations of individual polyphenols were carried out using a UPLC BEH C18 column (1.7 μm, 2.1 mm × 100 mm) at 30 °C. The samples (10 μL) were injected, and the elution was completed in 15 min with a sequence of linear gradients and isocratic flow rates of 0.45 mL/min. The mobile phase consisted of solvent A (0.1% formic acid, v/v) and solvent B (100% acetonitrile). The program began with isocratic elution with 99% solvent A (0--1 min), and then, a linear gradient was used until 12 min, lowering solvent A to 0%; from 12.5 to 13.5 min, the gradient returned to the initial composition (99% A), and then, it was held constant to re-equilibrate the column. The analysis was carried out using full-scan, data-dependent MS scanning from *m*/*z* 100 to 1500. Leucine enkephalin was used as the reference compound at a concentration of 500 pg/μL, at a flow rate of 2 μL/min, and the \[M − H\]^−^ ion at 554.2615 Da was detected. The \[M − H\]^−^ ion was detected during 15 min analysis performed within ESI--MS accurate mass experiments, which were permanently introduced via the LockSpray channel using a Hamilton pump. The lock mass correction was ±1.000 for the mass window. The mass spectrometer was operated in negative- and positive-ion mode, set to the base peak intensity (BPI) chromatograms, and scaled to 12,400 counts per second (cps) (100%). The optimized MS conditions were as follows: capillary voltage of 2500 V, cone voltage of 30 V, source temperature of 100 °C, desolvation temperature of 300 °C, and desolvation gas (nitrogen) flow rate of 300 L/h. Collision-induced fragmentation experiments were performed using argon as the collision gas, with voltage ramping cycles from 0.3 to 2 V. Characterization of the single components was carried out via the retention time and the accurate molecular masses. Each compound was optimized to its estimated molecular mass \[M − H\]^−^/\[M + H\]^+^ in the negative and positive mode before and after fragmentation. The data obtained from UPLC-MS were subsequently entered into the MassLynx 4.0ChromaLynx Application Manager software. On the basis of these data, the software is able to scan different samples for the characterized substances. The PDA spectra were measured over the wavelength range of 200--800 nm in steps of 2 nm. The calibration curves were prepared for the standard: gallic acid (y = 1222.5x − 1972.7; *r*^2^ = 0.9999), procyanidin B2 (y = 6566.2x − 15,957; *r*^2^ = 0.9999), (+)-catechin (y = 1565.9x + 2243; *r*^2^ = 0.9999), *p*-coumaric acid (y = 68.109x + 49.224; *r*^2^ = 0.9996), ferulic acid (y = 50,215x + 36,206; *r*^2^ = 0.9997), 5-caffeoylquinic acid (y = 14,332x + 1315.1; *r*^2^ = 0.9999), procyanidin A2 (y = 9484.1x − 6770.5; *r*^2^ = 0.9997), caffeic acid (y = 17,431x + 40,114; *r*^2^ = 0.9999), quercetin 3-*O*-rutinoside (y = 13,362x − 1795; *r*^2^ = 0.9997), qercetin-3-*O*-galactoside (y = 20,926x − 18,309; *r*^2^ = 0.9991), qercetin-3-*O*-glucoside (y = 11,923x + 8188; *r*^2^ = 0.9999), kaempferol 3-*O*-galactoside (y = 12,057x − 1922.4; *r*^2^ = 0.9997), ellagic acid (y = 26754x + 172359; *r*^2^ = 0.9995), cyanidin-3-*O*-glucoside (y = 30,726x + 190,297; *r*^2^ = 0.9976), and (−)-epicatechin (y = 39,233x − 360,853; *r*^2^ = 0.9994) at concentrations ranging between 0.05 and 0.5 mg/mL. All data were obtained in triplicate. The results were expressed as mg/100 g of dry basis (d.b.).

3.3. Pro-Health Properties {#sec3dot3-pharmaceuticals-13-00191}
--------------------------

### 3.3.1. Antiradical Capacity {#sec3dot3dot1-pharmaceuticals-13-00191}

Samples (1 g) were mixed with methanol (80%; 10 mL) and then with hydrochloric acid (1%). This process was performed twice by incubating the above slurry for 20 min under sonication. Next, the slurry was centrifuged at 19,000× *g* for 10 min, and the supernatant was filtered through a hydrophilic PTFE 0.20 μm membrane (Merck, Darmstadt, Germany) and used for analysis.

The ABTS method was carried out with the method described by Re et al. \[[@B40-pharmaceuticals-13-00191]\]. For this, 0.03 mL of sample was mixed with 3 mL of ABTS + solution, and after 6 min of reaction, the absorbance was measured at 734 nm using the spectrophotometer. All data were obtained in triplicate. The activity was expressed in mmol Trolox/g d.b.

### 3.3.2. Reducing Potential {#sec3dot3dot2-pharmaceuticals-13-00191}

The FRAP method was carried out with the method described by Benzie et al. \[[@B41-pharmaceuticals-13-00191]\]. The reagent was prepared by mixing 10 mmol 2,4,6-Tris(2-pyridyl)-s-triazine (TPTZ)/L reagent with 20 mmol/L ferric chloride in acetate buffer (pH 3.6). Precisely, 0.1 mL of sample was mixed with 0.9 mL of distilled water and 3 mL of ferric complex. After 10 min of reaction, the absorbance was measured at 593 nm using the spectrophotometer. All data were obtained in triplicate. The activity was expressed in mmol Trolox/g d.b.

### 3.3.3. Determination of Enzyme Inhibition Potency {#sec3dot3dot3-pharmaceuticals-13-00191}

Anti-diabetic activity, α-amylase, α-glucosidase inhibitory, and lipase activity effect of the materials were described previously by Nakai et al. \[[@B42-pharmaceuticals-13-00191]\], Podsędek et al. \[[@B43-pharmaceuticals-13-00191]\], and Nickavar et al. \[[@B44-pharmaceuticals-13-00191]\]. The extraction of mixed material was done with 70% acetone (or water) at room temperature for 60 min with constant stirring. After centrifuging at 4000 rpm for 10 min, and filtration, the supernatants were concentrated at 40 °C (vacuum evaporator) to remove the acetone and the aqueous phase was diluted with water. For further analytical and biological activity assays, a gradient of concentrations was prepared via serial dilution of the fruit extracts in pure water. The amount of the inhibitor (expressed as mg of fruit per 1 mL of reaction mixture under assay conditions) required to inhibit 50% of the enzyme activity was defined as the IC~50~ value. The IC~50~ of the fruits tested was obtained from the line of the plot of the fruit concentration in 1 mL of reaction mixture versus the % inhibition. All samples were assayed in triplicate.

### 3.3.4. Antiproliferative Potency {#sec3dot3dot4-pharmaceuticals-13-00191}

#### Cell Lines and Cell Culture

The human cancer cell lines BxPC3 (pancreatic ductal adenocarcinoma), DLD-1 (colorectal adenocarcinoma), and HCV29T (bladder cancer) were cultured in DMEM culture medium with 10% FBS and Antibiotic-Antimycotic Solution. Jurkat cell line (T-cell leukemia) was maintained in RPMI 1640 culture medium supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% fetal bovine serum (FBS). All cell lines were cultured at 37 °C in a humidified atmosphere of 5% CO~2~. The cells were seeded at densities of 5 × 10^3^ cells/0.1 mL (0.32 cm^2^) for cell viability assay. All cell lines were obtained from the collection of the Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.

#### Determination of Cell Viability

For determination of cell viability, cells were seeded in 96-well-plate (NUNC, Roskilde, Denmark). The plant extract was prepared by suspending 100 mg of dry plant material in 1 mL of 30% ethanol. The suspension was heated at 50 °C for 30 min and then centrifuged at 10,000× *g* for 15 min. The clear supernatant was diluted 30-fold in cell culture medium. As a control, 1% ethanol in the cell medium was used. The cells were incubated in 200 µL of the above culture medium for 48 h. Following the incubation, 20 µL of MTS solution was added to each well for 4 h; next, absorbance at 490 nm was recorded by a plate reader. Each treatment within a single experiment was performed in triplicate. Data were normalized to control medium containing 1% ethanol.

3.4. Statistical Analysis {#sec3dot4-pharmaceuticals-13-00191}
-------------------------

Statistical analysis such as one-way ANOVA (*p* \< 0.05) was analyzed using Statistica 12.5 (StatSoft, Kraków, Poland).

4. Conclusions {#sec4-pharmaceuticals-13-00191}
==============

It needs to be noted that the flowers and leaves of *S. officinalis* L. are a good source of polyphenols, including hydrolyzable tannins, phenolic acids, flavonols, and anthocyanins, and exhibit a significant antiradical and reducing potential. In turn, the roots and stalks are a valuable source of flavan-3-ols. The most effective the inhibition of α-amylase, α-glucosidase, and pancreatic lipase and antiproliferative activities, reflected in the inhibition of viability of pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, and bladder cancer as well as T-cell leukemia cell, were shown by the flowers and leaves of *S. officinalis* L. Thus, the data provided in this work indicate the possibility of using its individual morphological parts in the prevention of selected disease entities. In addition, this plant material can be used not only in the food industry as a functional additive to food, increasing its health value, but also in the cosmetic and pharmaceutical industries as a nutraceutical. The data obtained justify the need for further research on the morphological parts of *S. officinalis* L. with special emphasis put on leaves and flowers, to identify mechanisms potentially responsible for the antiproliferative activity.

The work was created in a leading research team "Food&Health".

The following are available online at <https://www.mdpi.com/1424-8247/13/8/191/s1>. Figure S1: LC-DAD-ESI-QTOF-MS/MS chromatogram fragile of the *Sanguisorba officinalis* L. flowers extract at 320 and 360 nm; Figure S2: LC-DAD-ESI-QTOF-MS/MS chromatogram fragile of the *Sanguisorba officinalis* L. leaves extract at 320 and 360 nm; Figure S3: LC-DAD-ESI-QTOF-MS/MS chromatogram fragile of the *Sanguisorba officinalis* L. roots extract at 320 and 360 nm; Figure S4: LC-DAD-ESI-QTOF-MS/MS chromatogram fragile of the *Sanguisorba officinalis* L. stalks extract at 320 and 360 nm.
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![Cell viability of Jurkat (**A**), BxPC3 (**B**), DLD-1 (**C**), and HCV29T (**D**) cell lines after treatment with plant extracts for 48 h. Data are presented as means SD normalized to untreated control (1% ethanol).](pharmaceuticals-13-00191-g001){#pharmaceuticals-13-00191-f001}
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###### 

Characterization of polyphenolic compounds in *Sanguisorba officinalis* L. by LC-DAD-ESI-QTOF-MS/MS.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No                                Compounds                                                          Rt \[min\]   Δ \[nm\]      MS/MS                             F ^‡^   L   R   S
  --------------------------------- ------------------------------------------------------------------ ------------ ------------- --------------------------------- ------- --- --- ---
  Hydrolyzable Tannins                                                                                                                                                              

  1                                 2,3-HHDP-(α/β)-glucose                                             1.31         272           481/463/301                                   x   

  2                                 HHDP-hex(2,3-(*S*)-Hexahydroxydiphenoyl-[d]{.smallcaps}-glucose)   1.34         314           481/332/301/182                   x       x   x   x

  3                                 HHDP-hexoside(1-galloyl-2,3-hexahydroxydiphenoyl-α-glucose)        1.41         218           481/301/275/257/229                       x       

  4                                 HHDP-hex(2,3-(*S*)-Hexahydroxydiphenoyl-[d]{.smallcaps}-glucose)   1.50         314           481/330/306/301/203/182           x       x   x   x

  5                                 Galloyl-hexoside(β-glucogallin)                                    1.86         278           331/169                                       x   

  6                                 Galloyl-pentoside                                                  1.99         274           301/169                                       x   

  7                                 Galloyl-hexoside                                                   2.08         272           331/169                                       x   

  8                                 Galloyl-hexoside                                                   2.09         268           331/169                                   x       

  10                                Galloyl-hexoside                                                   2.52         278           331/169                                   x       x

  13                                Galloyl-hexoside                                                   3.08         273           331/169                                   x       

  14                                Di-galloyl-HHDP-glucose (tellimagrandin I)                         3.16         236/322       785/633/615/483/301               x       x       x

  15                                Di-HHDP-glucose (pedunculagin isomer)                              3.34         230, 275 sh   783/481/301/257                   x       x   x   x

  17                                Methyl-6-*O*-galloyl-β-D-glucopyranoside                           3.54         274           345/169/124.99                                x   x

  18                                Pedunculagin1                                                      3.67         279           783/481/301                       x               

  20                                Di-HHDP-glucose (pedunculagin isomer)                              3.90         230, 275 sh   783/481/301/257                   x               

  23                                Pedunculagin1                                                      4.05         324           783/481/301                       x               

  24                                Di-HHDP-glucose (pedunculagin isomer)                              4.15         230, 275 sh   783/481/301/257                   x               

  25                                Galloyl-HHDP-glucose (corilagin isomer)                            4.18         235, 280 sh   633/300.99                                    x   

  26                                Di-HHDP-glucose (pedunculagin isomer)                              4.24         326           783/481/301/257                           x       

  27                                Di-HHDP-glucose (pedunculagin isomer)                              4.24         230, 275 sh   783/481/301/257                   x           x   

  28                                β-1-*O*-galloyl-2,3-(S)-HHDP-[d]{.smallcaps}-glucose               4.30         326           633/617/595/515/454/432/\         x       x       x
                                                                                                                                  319/297/179                                       

  29                                Pedunculagin1                                                      4.30         279           783/481/301                                   x   

  30                                Di-HHDP-glucose (pedunculagin isomer)                              4.40         313           783/613/447/423/274/211/\         x       x       x
                                                                                                                                  196/169                                           

  34                                Di-HHDP-glucoside                                                  4.54         273           783/481/301                                   x   

  35                                Methylellagic acid-pentose                                         4.55         324           447/315/301                       x       x       x

  37                                Di-galloyl-glucoside                                               4.59         273           483/313/169                                   x   

  44                                Galloyl-HHDP-glucose                                               4.98         219/276       633/463/301                       x       x   x   x

  47                                HHDP-NHTP-glucose (castalagin/vescalagin)                          5.08         219           933/915/889/871/631/613/587/569   x       x   x   x

  49                                HHDP-glucose                                                       5.30         222           481/301                           x       x   x   x

  50                                Methyl-4,6-digalloyl-β-[d]{.smallcaps}-glucopyranoside             5.39         212           497/345/169                       x       x   x   x

  51                                HHDP-NHTP-glucose (castalagin/vescalagin)                          5.44         282/343       933/915/889/871/631/613/587/569               x   

  53                                HHDP-galloyl-glucose                                               5.50         318           633/463/301/273/257/229/201/185   x               

  54                                Galloylglucoronide                                                 5.52         276           345/169                                       x   

  55                                Galloyl-HHDP-glucose (corilagin isomer)                            5.55         218           633/463/301                               x       

  56                                Di-galloyl-HHDP-glucose (tellimagrandin I)                         5.63         230, 280 sh   785/633/615/483/301               x       x       

  58                                Castalagin/vescalagin isomer                                       5.69         230, 285 sh   933/915/889/871/631/613/587/569   x       x       

  60                                Ellagic acid-pentoside                                             5.73         330           433/300.99                        x       x       x

  62                                Methyl-4,6-digalloyl-β-[d]{.smallcaps}-glucopyranoside             5.90         216           497/345/169                       x       x   x   x

  64                                Methyl-6-*O*-galloyl-β-[d]{.smallcaps}-glucopyranoside             5.97         374           345/169/124.99                    x       x       x

  66                                Di-galloyl-HHDP-glucose (tellimagrandin I)                         6.01         203/279       785/633/615/483/301                           x   

  67                                Ellagic acid hexoside1                                             6.05         251/362       463/301                           x       x   x   x

  68                                Ellagic acid hexoside                                              6.09         329           463/301                                           x

  70                                Castalagin/vescalagin isomer                                       6.15         230, 285 sh   933/915/889/871/631/613/587/569               x   

  71                                Methyl-4,6-digalloyl-β-D-glucopyranoside                           6.19         213           497/345/169                               x   x   x

  72                                Di-galloyl hexoside                                                6.22         203           483/301/169                                   x   

  73                                Eucaglobulin                                                       6.23         276           497/345/327/313/183/169           x       x       x

  75                                Eucaglobulin                                                       6.25         270           497/345/327/313/183/169           x       x       x

  77                                Galloyl-HHDP-hexoside                                              6.30         215           633/301                                       x   

  79                                Castalagin/vescalagin isomer                                       6.37         230, 285 sh   933/915/889/871/631/613/587/569   x       x   x   x

  81                                Castalagin/vescalagin isomer                                       6.41         222           933/915/889/871/631/613/587/569           x   x   x

  82                                HHDP-NHTP-glucose-galloyl-di-HHDP-glucose (cocciferind2)           6.46         224           933/915/633/631/301               x       x   x   x

  84                                Galloyl-bis-HHDP-glucose (potentilin/casuarictin isomer)           6.51         221           935/917/873//783/633/301          x       x   x   x

  85                                Galloyl-bis-HHDP-glucose (potentilin/casuarictin isomer)           6.55         225, 280 sh   935/917/873//783/633/301                      x   

  86                                Lambertianin C                                                     6.58         250           1401/1237/935/633303              x       x   x   x

  88                                Methyl-4,6-digalloyl-β-D-glucopyranoside                           6.66         212           497/345/169                                   x   

  92                                Trigalloyl-HHDP-glucose                                            6.93         251 nm        937/767/635/465/301                           x   

  93                                Ellagic acid-hexoside-pentoside                                    6.99         253/361       595/433/301                       x       x   x   x

  94                                Ellagic acid-hexoside-pentoside                                    7.04         247/361       595/433/301                               x       

  95                                Galloyl-bis-HHDP-glucose (potentilin/casuarictin isomer)           7.06         253/357       935/917/873//783/633/301                      x   

  97                                Galloyl-bis-HHDP-glucose (potentilin/casuarictin isomer)           7.13         221           935/917/873//783/633/301          x               

  98                                Castalagin/vescalagin isomer                                       7.14         230, 285 sh   933/915/889/871/631/613/587/569                   x

  99                                Ellagic acid pentoside                                             7.23         254/361       433/301                           x       x   x   x

  100                               Tetragalloyl-glucose                                               7.27         227           787/635/617/573/465/403                       x   

  102                               Ellagic acid hexoside                                              7.34         254/362       463/301                           x       x   x   x

  104                               Galloyl-bis-HHDP-glucose (potentilin/casuarictin isomer)           7.41         218           935/917/873//783/633/301                  x       

  106                               Galloyl-bis-HHDP-glucose (potentilin/casuarictin isomer)           7.43         219           935/917/873//783/633/301          x           x   

  108                               Ellagic acid ^a^                                                   7.50         255/365       300.99                            x       x   x   x

  110                               Castalagin/vescalagin isomer                                       7.81         250/373       933/915/889/871/631/613/587/569               x   

  111                               Pentagalloylglucoside                                              8.04         280           939/769/617/465/313/169                       x   

  113                               Methyl galloyl-glucoside                                           8.24         297/325       345/183                                   x       

  114                               Trigalloyl-HHDP- glucose                                           8.26         259/360       937/7767/301                                  x   

  115                               Trigalloyl-β-*D*-methyl glucoside                                  8.35         263/356       649/497/479/345                               x   

  118                               Di-galloyl hexoside                                                8.54         261/374       483/301                                       x   

  127                               3,3′,4′-*O*-trimethyl ellagic acid                                 9.66         352           343/328                                   x       

  128                               3,3′,4′-*O*-trimethyl ellagic acid                                 9.79         353           343/328                                   x       

  129                               3,4′-*O*-dimethyl ellagic acid                                     10.55        249/359       329/314/298/285                               x   

  130                               3,4′-*O*-dimethyl ellagic acid                                     11.11        247/362       329/314/298/285                               x   

  Sanguiin                                                                                                                                                                          

  11                                Sanguiin H-6                                                       2.74         234/320       1870/1567/1265/933/631/301        x       x       x

  41                                Sanguiin H-4                                                       4.84         235/280 sh    633/300.99                        x               

  48                                Sanguiin H-10 isomer                                               5.23         313           1567/1265/1103/933/301            x       x       x

  65                                Sanguiin H-1                                                       5.99         230/280 sh    785/633/465/301                   x               

  69                                Sanguiin H-1                                                       6.13         254/371       785/633/465/301                           x   x   x

  89                                Sanguiin H-6                                                       6.75         236           1870/1567/1265/933/631/301        x       x   x   x

  96                                Sanguiin H-1                                                       7.12         221           785/633/465/301                           x   x   

  119                               Sanguiin H-7                                                       8.59         261/361       801/649/301                                   x   

  122                               Sanguiin H-7 isomer                                                9.05         334           801/649/301                       x       x       x

  Sanguisorbic acids                                                                                                                                                                

  9                                 Sanguisorbic acid dilactone                                        2.13         272           469/314/301/286                           x   x   

  12                                Sanguisorbic acid dilactone                                        2.89         275           469/314/301/286                               x   

  52                                Sanguisorbic acid glucoside                                        5.47         325           667/285                                   x       x

  Phenolic acids                                                                                                                                                                    

  16                                Caffeoylquinic acid ^a^                                            3.50         322           353/191/179/161                   x       x       

  19                                3-*O*-caffeoylquinic acid ^a^                                      3.72         323           353/191/179/135                   x       x       x

  32                                3-*O-p*-coumaroylquinic acid ^a^                                   4.50         311           337163                            x       x       

  33                                Rosmarinic acid                                                    4.54         325           359/191/179/173/163/152                   x       x

  42                                5-*O*-caffeoylquinic acid ^a^                                      4.87         324           353/191/179                       x       x       x

  78                                3-*O*-feruloylquinic acid ^a^                                      6.36         324           367/193/191                       x       x       x

  116                               Disuccinoyl-caffeoylquinic acids                                   8.41         326           553/537/515/375/353/191/\         x       x       x
                                                                                                                                  179/173                                           

  120                               3,5-dicaffeoylquinic acid                                          8.83         326           515/353/191/179/173               x       x       x

  121                               3,5-dicaffeoylquinic acid                                          8.91         326           515/353/191/179/173               x       x       x

  123                               Caffeoyl dihexoside                                                9.27         325           503/341/179                       x       x       x

  124                               Caffeoyl dihexoside                                                9.36         313           503/341/179                       x       x       x

  125                               Caffeoyl dihexoside                                                9.50         326           503/341/179                       x       x       x

  126                               Caffeoyl dihexoside                                                9.64         326           503/341/179                                   x   

  Anthocyanins                                                                                                                                                                      

  21                                Cyanidin 3,5-*O*-diglucoside                                       3.91         520           611/449/287                       x               

  46                                Cyanidin 3-*O*-glucoside ^a^                                       5.05         516           449/287                           x               

  76                                Cyanidin 3-*O*-malonylglucoside                                    6.28         517           535/287                           x               

  87                                Cyanidin 3-*O*-rutinoside                                          6.60         518           595/449/287                       x               

  90                                Cyanidin 3-*O*-malonylglucoside                                    6.77         517           535/287                           x               

  91                                Cyanidin 3-(6-*O*-acetyl)-glucoside                                6.91         518           491/317/303/287                   x               

  Catechins and Proanthocyanidins                                                                                                                                                   

  31                                (+)-Catechin ^a^                                                   4.43         281           289                               x       x   x   x

  36                                B-type (epi)catechin dimmer ^a^                                    4.58         276           577/289                           x       x       x

  38                                B-type (epi)catechin dimmer ^a^                                    4.67         279           577/289                                   x   x   

  39                                B-type (epi)catechin dimmer ^a^                                    4.69         279           577/289                           x       x       x

  40                                (−)-Epicatechin ^a^                                                4.83         279           289                               x       x   x   x

  43                                B-type (epi)catechin trimmer                                       4.94         280           865/577/289                                       x

  57                                B-type (epi)catechin tetramer                                      5.63         278           1153/863/577/289                  x       x   x   x

  59                                B-type (epi)catechin tetramer                                      5.70         278           1153/863/577/290                  x       x   x   x

  63                                B-type (epi)catechin dimmer ^a^                                    5.90         274           577/289                           x       x   x   x

  74                                A-type procyanidins tetramer                                       6.23         221/273       1153/865/575/                                 x   

  80                                B-type (epi)catechin tetramer                                      6.41         278           1153/863/577/289                              x   

  83                                B-type (epi)catechin dimmer ^a^                                    6.46         276           577/289                                       x   

  Flavonols                                                                                                                                                                         

  45                                Quercetin 3-*O*-glucoside ^a^                                      5.03         358           463/301                                   x       x

  61                                Kaempferol-di-*O*-rhamnoside                                       5.80         350           577/431/285                       x       x       x

  101                               Quercetin 3-*O*-(6″-galloylglucose)                                7.30         224           615/463/300.027                           x       

  103                               Taxifolin 7-*O*-β-D-glucopyranoside                                7.35         229           465/285                                       x   

  105                               Quercetin-glucoside-rhamnoside-rhamnoside                          7.41         254/337       755/609/463/300.027               x       x       x

  107                               Quercetin rhamnosyl-rutinoside                                     7.47         368           755/609/301                       x       x       x

  109                               Quercetin 3-*O*-glucuronide                                        7.68         255/353       477/300.027                       x       x   x   x

  112                               Quercetin 3-*O*-acetyl glucoside                                   8.15         355           505/300.027                       x       x       x

  117                               Kaempferol 3-*O*-glucuronide                                       8.49         347           461/285                                   x       x

  Triterpenoid saponins                                                                                                                                                             

  22                                Sanguisorbigenin                                                   3.98         223/271       453/345/183/169                   x       x       x
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^‡^ F, flowers; L, leaves; R, roots; S, stalks; ^a^ identification confirmed by commercial standards.

pharmaceuticals-13-00191-t002_Table 2

###### 

Content of polyphenolic compounds in *Sanguisorba officinalis* \[mg/100 g d.w.\].

        Compounds                                                          Flower               Leaves              Roots               Stalk
  ----- ------------------------------------------------------------------ -------------------- ------------------- ------------------- ------------------
        Hydrolyzable tannins                                                                                                            
  1     2,3-HHDP-(α/β)-glucose                                             nd ^‡^               nd                  12.33 ± 0.25a ^†^   nd
  2     HHDP-hex(2,3-(*S*)-Hexahydroxydiphenoyl-[d]{.smallcaps}-glucose)   141.89 ± 2.84a       102.71 ± 2.05b      13.28 ± 0.27c       11.49 ± 0.23c
  3     HHDP-hexoside(1-galloyl-2,3-hexahydroxydiphenoyl-α-glucose)        nd                   14.36 ± 0.29a       nd                  nd
  4     HHDP-hex(2,3-(*S*)-Hexahydroxydiphenoyl-[d]{.smallcaps}-glucose)   161.00 ± 3.22a       63.35 ± 1.27b       40.73 ± 0.81c       12.49 ± 0.25d
  5     Galloyl-hexoside(β-glucogallin)                                    nd                   nd                  92.13±1.84a         nd
  6     Galloyl-pentoside                                                  nd                   nd                  38.51±0.77a         nd
  7     Galloyl-hexoside                                                   nd                   nd                  20.66±0.41a         nd
  8     Galloyl-hexoside                                                   nd                   13.89 ± 0.28a       nd                  nd
  10    Galloyl-hexoside                                                   nd                   5.18 ± 0.10b        nd                  9.52 ± 0.19a
  13    Galloyl-hexoside                                                   nd                   4.41 ± 0.09a        nd                  nd
  14    Di-galloyl-HHDP-glucose (tellimagrandin I)                         5.57 ± 0.11a         6.34 ± 0.13a        nd                  1.35 ± 0.03b
  15    Di-HHDP-glucose (pedunculagin isomer)                              100.66 ± 2.01b       24.25 ± 0.49c       136.03 ± 2.72a      15.78 ± 0.32d
  17    Methyl-6-*O*-galloyl-β-D-glucopyranoside                           nd                   nd                  234.27 ± 4.69a      7.20 ± 0.14b
  18    Pedunculagin1                                                      2.55 ± 0.05a         nd                  nd                  nd
  20    Di-HHDP-glucose (pedunculagin isomer)                              2.23 ± 0.04a         nd                  nd                  nd
  23    Pedunculagin1                                                      9.08 ± 0.18a         nd                  nd                  nd
  24    Di-HHDP-glucose (pedunculagin isomer)                              20.00 ± 0.40a        nd                  nd                  nd
  25    Galloyl-HHDP-glucose (corilagin isomer)                            nd                   nd                  29.73 ± 0.59a       nd
  26    Di-HHDP-glucose (pedunculagin isomer)                              nd                   17.21 ± 0.34a       nd                  nd
  27    Di-HHDP-glucose (pedunculagin isomer)                              97.32 ± 1.95a        nd                  42.58 ± 0.85b       nd
  28    β-1-*O*-galloyl-2,3-(S)-HHDP-[d]{.smallcaps}-glucose               513.20 ± 10.26a      433.89±8.68b        nd                  83.52 ± 1.67c
  29    Pedunculagin1                                                      nd                   nd                  24.37 ± 0.49a       nd
  30    Di-HHDP-glucose (pedunculagin isomer)                              9.66 ± 0.19b         11.96 ± 0.24a       nd                  2.01 ± 0.04c
  34    Di-HHDP-glucoside                                                  nd                   nd                  19.51 ± 0.39a       0
  35    Methylellagic acid-pentose                                         26.83 ± 0.54a        5.45 ± 0.11c        nd                  8.17 ± 0.16b
  37    Di-galloyl-glucoside                                               nd                   nd                  53.85 ± 1.08a       nd
  44    Galloyl-HHDP-glucose                                               165.31 ± 3.31a       8.65 ± 0.17c        145.15 ± 2.90b      5.25 ± 0.11d
  47    HHDP-NHTP-glucose (castalagin/vescalagin)                          87.29 ± 1.75b        100.59 ± 2.01a      41.30 ± 0.83c       23.36 ± 0.47d
  49    HHDP-glucose                                                       97.26 ± 1.95a        45.3 ± 0.91b        11.32 ± 0.23c       11.44 ± 0.23c
  50    Methyl-4,6-digalloyl-β-[d]{.smallcaps}-glucopyranoside             7.94 ± 0.16b         1.06 ± 0.02c        17.12 ± 0.34a       0.58 ± 0.01d
  51    HHDP-NHTP-glucose (castalagin/vescalagin)                          nd                   nd                  24.08 ± 0.48a       nd
  53    HHDP-galloyl-glucose                                               43.97 ± 0.88a        nd                  nd                  nd
  54    Galloylglucoronide                                                 nd                   nd                  93.44 ± 1.87a       nd
  55    Galloyl-HHDP-glucose (corilagin isomer)                            nd                   22.90 ± 0.46a       nd                  nd
  56    Di-galloyl-HHDP-glucose (tellimagrandin I)                         85.77 ± 1.72a        35.62 ± 0.71b       nd                  nd
  58    Castalagin/vescalagin isomer                                       37.38 ± 0.75a        70.71 ± 1.41b       nd                  nd
  60    Ellagic acid-pentoside                                             9.31 ± 0.19b         13.70 ± 0.27a       nd                  3.96 ± 0.08c
  62    Methyl-4,6-digalloyl-β-[d]{.smallcaps}-glucopyranoside             256.75 ± 5.14a       104.29 ± 2.09b      254.04 ± 5.08a      71.93 ± 1.44c
  64    Methyl-6-*O*-galloyl-β-[d]{.smallcaps}-glucopyranoside             6.75 ± 0.14b         10.71 ± 0.21a       nd                  3.47 ± 0.07c
  66    Di-galloyl-HHDP-glucose (tellimagrandin I)                         nd                   nd                  13.52 ± 0.27a       nd
  67    Ellagic acid hexoside                                              5.76 ± 0.12b         7.16 ± 0.14a        4.05 ± 0.08b        2.61 ± 0.05c
  68    Ellagic acid hexoside                                              nd                   nd                  nd                  4.53 ± 0.09a
  70    Castalagin/vescalagin isomer                                       nd                   nd                  68.46 ± 1.37a       nd
  71    Methyl-4,6-digalloyl-β-D-glucopyranoside                           nd                   1.80 ± 0.04a        1.70 ± 0.03a        0.58 ± 0.01b
  72    Di-galloyl hexoside                                                nd                   nd                  43.6±0.87a          nd
  73    Eucaglobulin                                                       51.84 ± 1.04b        102.83 ± 2.06a      nd                  16.79 ± 0.34c
  75    Eucaglobulin                                                       71.19 ± 1.42a        71.72 ± 1.43a       nd                  22.59 ± 0.45b
  77    Galloyl-HHDP-hexoside                                              nd                   nd                  106.23 ± 2.12a      nd
  79    Castalagin/vescalagin isomer                                       26.13 ± 0.52c        62.30 ± 1.25a       52.75 ± 1.06b       14.52 ± 0.29d
  81    Castalagin/vescalagin isomer                                       nd                   92.82 ± 1.86a       67.43 ± 1.35b       13.19 ± 0.26c
  82    HHDP-NHTP-glucose-galloyl-di-HHDP-glucose (cocciferind2)           87.01 ± 1.74b        41.02 ± 0.82c       155.76 ± 3.12a      13.57 ± 0.27d
  84    Galloyl-bis-HHDP-glucose (potentilin/casuarictin isomer)           38.45 ± 0.77b        132.33 ± 2.65a      32.87 ± 0.66c       30.56 ± 0.61c
  85    Galloyl-bis-HHDP-glucose (potentilin/casuarictin isomer)           nd                   nd                  52.26 ± 1.05a       nd
  86    Lambertianin C                                                     3029.28 ± 60.59a     2232.84 ± 44.66b    898.98 ± 17.98d     1236.77 ± 24.74c
  88    Methyl-4,6-digalloyl-β-D-glucopyranoside                           nd                   nd                  4.82 ± 0.1a         nd
  92    Trigalloyl-HHDP-glucose                                            nd                   nd                  86.34 ± 1.73a       nd
  93    Ellagic acid-hexoside-pentoside                                    33.54 ± 0.67a        32.53 ± 0.65a       32.80 ± 0.66a       7.09 ± 0.14b
  94    Ellagic acid-hexoside-pentoside                                    nd                   51.34 ± 1.03a       nd                  nd
  95    Galloyl-bis-HHDP-glucose (potentilin/casuarictin isomer)           nd                   nd                  12.48 ± 0.25a       nd
  97    Galloyl-bis-HHDP-glucose (potentilin/casuarictin isomer)           30.53 ± 0.61a        nd                  nd                  nd
  98    Castalagin/vescalagin isomer                                       nd                   nd                  nd                  43.38 ± 0.87a
  99    Ellagic acid pentoside                                             14.50 ± 0.29b        15.22 ± 0.3b        18.07 ± 0.36a       3.47 ± 0.07c
  100   Tetragalloyl-glucose                                               nd                   nd                  328.94 ± 6.58a      nd
  102   Ellagic acid hexoside1                                             1.14 ± 0.02a         0.33 ± 0.01c        0.61 ± 0.01b        0.36 ± 0.01c
  104   Galloyl-bis-HHDP-glucose (potentilin/casuarictin isomer)           nd                   56.41 ± 1.13a       nd                  nd
  106   Galloyl-bis-HHDP-glucose (potentilin/casuarictin isomer)           202.46 ± 4.05a       nd                  147.72 ± 2.95b      nd
  108   Ellagic acid                                                       17.69 ± 0.35c        26.90 ± 0.54a       13.49 ± 0.27b       5.20 ± 0.10d
  110   Castalagin/vescalagin isomer                                       nd                   nd                  1.91 ± 0.04a        nd
  111   Pentagalloylglucoside                                              nd                   nd                  36.57 ± 0.73a       nd
  113   Methyl galloyl-glucoside                                           nd                   13.75 ± 0.28a       nd                  nd
  114   Trigalloyl-HHDP- glucose                                           nd                   nd                  0.71 ± 0.01a        nd
  115   Trigalloyl-β-*D*-methyl glucoside                                  nd                   nd                  35.65 ± 0.71a       nd
  118   Di-galloyl hexoside                                                nd                   nd                  3.61 ± 0.07a        nd
  127   3,3′,4′-*O*-trimethyl ellagic acid                                 nd                   31.41 ± 0.63a       nd                  nd
  128   3,3′,4′-*O*-trimethyl ellagic acid                                 nd                   1.47 ± 0.03a        nd                  nd
  129   3,4′-*O*-dimethyl ellagic acid                                     nd                   nd                  49.05 ± 0.98a       nd
  130   3,4′-*O*-dimethyl ellagic acid                                     nd                   nd                  251.11 ± 5.02a      nd
        SUM                                                                5497.24 ± 109.94a    4090.71 ± 81.81b    3865.92 ± 77.32c    1686.73 ± 33.73d
        Sanguiin                                                                                                                        
  11    Sanguiin H-6                                                       2.57 ± 0.05b         10.13 ± 0.20a       nd                  1.22 ± 0.02c
  41    Sanguiin H-4                                                       352.14 ± 7.04a       nd                  nd                  nd
  48    Sanguiin H-10 isomer                                               130.92 ± 2.62a       5.33 ± 0.11b        nd                  4.14 ± 0.08b
  65    Sanguiin H-1                                                       43.36 ± 0.87         nd                  nd                  nd
  69    Sanguiin H-1                                                       nd                   1.01 ± 0.02b        2.95 ± 0.06a        0.15 ± 0.01c
  89    Sanguiin H-6                                                       3566.15 ± 71.32a     621.04 ± 12.42d     763.91 ± 15.28c     289.86 ± 5.80b
  96    Sanguiin H-1                                                       nd                   61.95 ± 1.24b       730.22 ± 14.60a     nd
  119   Sanguiin H-7                                                       nd                   nd                  4.42 ± 0.09a        nd
  122   Sanguiin H-7 isomer                                                1.89 ± 0.04a         2.24 ± 0.04a        nd                  0.98 ± 0.02b
        SUM                                                                4097.03 ± 81.94a     701.7 ± 14.03c      1501.5 ± 30.03b     296.35 ± 5.93d
        Sanguisorbic acids                                                                                                              
  9     Sanguisorbic acid dilactone                                        nd                   6.61 ± 0.13d        10.95 ± 0.22a       nd
  12    Sanguisorbic acid dilactone                                        nd                   nd                  15.44 ± 0.31a       nd
  52    Sanguisorbic acid glucoside                                        nd                   109.18 ± 2.18a      nd                  13.43 ± 0.27b
        SUM                                                                nd                   115.79 ± 2.32a      26.39 ± 0.53b       13.43 ± 0.27c
        Phenolic acids                                                                                                                  
  16    Caffeoylquinic acid                                                23.07 ± 0.46b        47.52 ± 0.95a       nd                  nd
  19    Caffeoylquinic acid                                                539.00 ± 10.78b      1363.67 ± 27.27a    nd                  182.92 ± 3.66c
  32    3-*p*-Coumaroylquinic acid                                         87.17 ± 1.74a        42.55 ± 0.85b       nd                  nd
  33    Rosmarinic acid                                                    nd                   8.39 ± 0.17a        nd                  2.98 ± 0.06b
  42    5-Caffeoylquinic acid                                              673.42 ± 13.47a      436.44 ± 8.73b      nd                  129.09 ± 2.58c
  78    3-Feruloylquinic acid                                              11.46 ± 0.23a        4.95 ± 0.10b        nd                  3.17 ± 0.06c
  116   Disuccinoyl-caffeoylquinic acids                                   69.02 ± 1.38b        89.00 ± 1.78a       nd                  31.51 ± 0.63c
  120   Di-caffeoylquinic                                                  4.81 ± 0.10b         17.66 ± 0.35a       nd                  2.79 ± 0.06c
  121   Dicaffeoylquinic                                                   4.12 ± 0.08c         12.78 ± 0.26a       nd                  1.33 ± 0.03c
  123   Caffeoyl dihexoside                                                2.72 ± 0.05b         6.68 ± 0.13a        nd                  3.10 ± 0.06b
  124   Caffeoyl dihexoside                                                13.38 ± 0.27a        8.47 ± 0.17b        nd                  2.04 ± 0.04c
  125   Caffeoyl dihexoside                                                3.51 ± 0.07b         6.26 ± 0.13a        nd                  2.23 ± 0.04c
  126   Caffeoyl dihexoside                                                nd                   nd                  6.64 ± 0.13a        nd
        SUM                                                                1431.68 ± 28.63b     2044.37 ± 40.89a    6.64 ± 0.13d        361.16 ± 7.22c
        Anthocyanins                                                                                                                    
  21    Cyanidin 3,5-*O*-diglucoside                                       19.56 ± 0.39a        nd                  nd                  nd
  46    Cyanidin 3-*O*-glucoside                                           339.87 ± 6.80a       nd                  nd                  nd
  76    Cyanidin 3-*O*-malonylglucoside                                    154.35 ± 3.09a       nd                  nd                  nd
  87    Cyanidin 3-*O*-rutinoside                                          4.83 ± 0.10a         nd                  nd                  nd
  90    Cyanidin 3-*O*-malonylglucoside                                    14.40 ± 0.29a        nd                  nd                  nd
  91    Cyanidin 3-(6-*O*-acetyl)glucoside                                 16.56 ± 0.33a        nd                  nd                  nd
        SUM                                                                549.57 ± 10.99a      nd                  nd                  nd
        Catechins and Proanthocyanins                                                                                                   
  31    (+)-Catechin                                                       46.77 ± 0.94d        160.08 ± 3.20b      374.41 ± 7.49a      133.37 ± 2.67c
  36    B-type (epi)catechin dimmer                                        111.05 ± 2.22a       33.03 ± 0.66b       nd                  28.85 ± 0.58c
  38    B-type (epi)catechin dimmer                                        nd                   19.88 ± 0.40b       383.49 ± 7.67a      nd
  39    B-type (epi)catechin dimmer                                        136.33 ± 2.73a       15.04 ± 0.30c       nd                  125.77 ± 2.52b
  40    (−)-Epicatechin                                                    656.57 ± 13.13b      138.19 ± 2.76d      700.12 ± 14.00a     457.66 ± 9.15c
  43    B-type (epi)catechin trimmer                                       nd                   nd                  nd                  86.20 ± 1.72a
  57    B-type (epi)catechin tetramer                                      120.62 ± 2.41c       45.32 ± 0.91d       448.56 ± 8.97a      142.85 ± 2.86b
  59    B-type (epi)catechin tetramer                                      57.12 ± 1.14a        22.38 ± 0.45b       21.69 ± 0.43b       18.43 ± 0.37c
  63    B-type (epi)catechin dimmer                                        760.26 ± 15.21b      305.55 ± 6.11c      796.86 ± 15.94a     214.39 ± 4.29d
  74    A-type procyanidin tetramer                                        nd                   nd                  51.53 ± 1.03a       nd
  80    B-type (epi)catechin tetramer                                      nd                   nd                  105.67 ± 2.11a      nd
  83    B-type (epi)catechin dimmer                                        nd                   nd                  356.86 ± 7.14a      nd
        SUM                                                                1888.72 ± 37.77b     739.47 ± 14.79d     3239.19 ± 64.78a    1207.52 ± 24.15c
        Flavonols                                                                                                                       
  45    Quercetin 3-*O*-glucoside                                          nd                   15.00 ± 0.30a       nd                  4.15 ± 0.08b
  61    Kaempferol-di-*O*-rhamnoside                                       5.23±0.10a           0.59 ± 0.01b        nd                  0.31 ± 0.01b
  101   Quercetin 3-*O*-(6″-galloylglucose)                                nd                   77.72 ± 1.55a       nd                  nd
  103   Taxifolin 7-*O*-β-D-glucopyranoside                                nd                   nd                  43.41 ± 0.87a       nd
  105   Quercetin-glucoside-rhamnoside-rhamnoside                          26.29 ± 0.53a        9.93 ± 0.20c        nd                  13.33 ± 0.27b
  107   Quercetin rhamnosyl-rutinoside                                     5.93 ± 0.12a         3.11 ± 0.06b        nd                  2.54 ± 0.05b
  109   Quercetin 3-*O*-glucuronide                                        494.97 ± 9.90c       1645.76 ± 32.92a    4.13 ± 0.08d        675.15 ± 13.50b
  112   Quercetin 3-*O*-acetyl glucoside                                   47.89 ± 0.96b        54.56 ± 1.09a       nd                  26.73 ± 0.53c
  117   Kaempferol 3-*O*-glucuronide                                       137.89 ± 2.76b       163.18 ± 3.26a      nd                  65.65 ± 1.31c
        SUM                                                                718.2 ± 14.36c       1969.85 ± 39.40a    47.54 ± 0.95d       787.86 ± 15.76b
        Sanguisorbigenin                                                   262.53 ± 5.25b       300.60 ± 6.01a      nd                  253.28 ± 5.07c
        Total mg/100 g d.w.                                                14444.97 ± 288.90a   9962.55 ± 199.25b   8687.16 ± 173.74c   4606.33 ± 92.13d

^†^ Values are expressed as the mean (*n* = 3) ± standard deviation and different letters (between morphological parts) within the same row indicates statistically significant differences (*p* \< 0.05); ^‡^ nd, not identified.

pharmaceuticals-13-00191-t003_Table 3

###### 

The antioxidant activity and the biological activity in vitro.

  Components   α-Amylase \[EC~50~ MG/ML\]   α-Glucosidase \[EC~50~ MG/ML\]   Pancreatic Lipase \[EC~50~ MG/ML\]   ABTS \[mmol/g d.b.\]   FRAP \[mmol/g d.b.\]
  ------------ ---------------------------- -------------------------------- ------------------------------------ ---------------------- ----------------------
  Leaves       9.48 ± 0.24b ^‡^             11.86 ± 0.24b                    18.75 ± 0.38a                        6.63 ± 0.1a3           0.30 ± 0.01a
  Flowers      6.03 ± 0.19a                 9.60 ± 0.19a                     21.40 ± 0.43b                        5.56 ± 0.11b           0.20 ± 0.01b
  Stalks       23.91 ± 0.63c                31.74 ± 0.63d                    56.47 ± 1.13c                        0.52 ± 0.01d           0.09 ± 0.01d
  Roots        10.44 ± 0.39b                19.54 ± 0.39c                    72.68 ± 1.45d                        5.08 ± 0.10c           0.13 ± 0.01c

^‡^ Values are expressed as the mean (*n* = 3) ± standard deviation and different letters (between morphological parts) within the same row indicates statistically significant differences (*p* \< 0.05).
